Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus TPC in anti-PD-1 resistant nasopharyngeal carcinoma
NCT06664983Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cadonilimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 12 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06664983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664983.